

Alterations of Alpha₁ and Alpha₂ Adrenoceptor-mediated Pressor Responses by Halothane and Isoflurane Anesthesia

Dermot Kenny, M.B., M.R.C.P.I.,* Lorie R. Pelc, Ph.D.,† Harold L. Brooks, M.D.,‡ John P. Kampine, M.D., Ph.D.,§ William T. Schmeling, M.D., Ph.D.,† David C. Warltier, M.D., Ph.D.¶

The mechanism by which halothane and isoflurane interfere with catecholamine-mediated vasoconstriction was investigated, utilizing selective agonists of postjunctional alpha₁ and alpha₂ adrenoceptors in chronically instrumented dogs. After ganglionic, cholinergic, and beta adrenergic blockade, dose responses to phenylephrine (0.3–1.2 µg/kg, iv), a selective alpha₁ adrenoceptor agonist, and azepexole [B-HT 933] (5–20 µg/kg, iv), a selective alpha₂ adrenoceptor agonist, were obtained in conscious dogs. Each dog was subsequently anesthetized with either halothane (1.7%) or isoflurane (2%) in oxygen in equihypotensive concentrations. After a 1 h equilibration period, the dose response curves were repeated. Twenty experiments in ten chronically instrumented dogs were completed. Halothane and isoflurane produced significant ($P < 0.05$) attenuation of both the increase in systolic and diastolic arterial pressure after bolus administration of all doses of phenylephrine and azepexole. No specific selectivity of either volatile anesthetic for alpha₁ or alpha₂ mediated pressor responses was found. Therefore, in chronically instrumented dogs, alpha₁- and alpha₂-mediated pressor responses were similarly influenced by halothane and isoflurane. The present results suggest that both halothane and isoflurane act as functional antagonists to alpha adrenergic mediated vasoconstriction. (Key words: Anesthetics, volatile: halothane; isoflurane. Sympathetic nervous system, alpha adrenergic agonists: azepexole; phenylephrine. Receptors, adrenergic: alpha₁; alpha₂.)

VASOCONSTRICTION in both the systemic and coronary circulation can be produced by endogenous circulating and neuronally released catecholamines which act at postjunctional alpha₁ and alpha₂ adrenergic receptors located on vascular smooth muscle membranes.¹ In addition to causing an abrupt vasoconstriction when stimulated, alpha adrenergic receptors are involved in the maintenance of vascular tone.² Certain vasodilator agents not classified as alpha adrenergic antagonists have been previously shown to interact with alpha₁ and/or alpha₂ adrenoceptors attenuating pressor responses mediated by selective alpha₁ or alpha₂ agonists.³ The mechanism whereby various va-

sodilators decrease the pressor response to stimulation of either alpha₁ or alpha₂ receptors by highly selective agonists has not been well elucidated.

The influence of the volatile anesthetics on alpha adrenergic pressor responses has only recently been investigated. Both halothane and isoflurane have been shown to produce a reduction in arterial pressure by decreasing vascular resistance and cardiac output; however, isoflurane has been demonstrated to cause a more pronounced vasodilation than halothane.^{4,5} Whether the greater effect of isoflurane on the peripheral vasculature was mediated through a differential attenuation of the response to alpha receptor stimulation is unknown. It has been suggested that halothane may selectively attenuate alpha₂ adrenoceptor-mediated vasoconstriction;⁶ however, whether a portion of the vasodilator action of isoflurane is due to an interaction at either postjunctional vascular alpha₁ or alpha₂ adrenoceptors has not been studied.

Previous work demonstrating a depression of the vascular response to selective alpha agonists by halothane was performed in pithed rats and isolated vascular rings.⁶ In addition, results from another study in pithed rats⁷ in which pressor responses elicited by a selective alpha₂ agonist were described to be reduced by calcium channel blocking agents have been demonstrated to be at variance with investigations performed in conscious dogs and primates.⁸

The objective of the present investigation was to delineate the effects of halothane and isoflurane on selected hemodynamic responses following selective stimulation of alpha₁ and alpha₂ adrenergic receptors by phenylephrine and azepexole, respectively.⁹ This work was performed in chronically instrumented dogs to eliminate any potential interaction with basal anesthesia¹⁰ and to afford a direct comparison between the conscious and anesthetized state. Furthermore, all experiments were completed in the presence of cholinergic, beta adrenergic, and ganglionic blockade to eliminate any indirect reflex-induced actions of alpha₁ and alpha₂ agonists.¹¹ Thus, the direct effect of alpha agonists with alpha adrenoceptors in the absence and presence of volatile anesthetics was examined.

Methods

ANIMAL INSTRUMENTATION

The dogs used in this study were maintained in accordance with the guidelines of the Animal Care Committee

* Fellow in Cardiology.

† Assistant Professor of Anesthesiology and Pharmacology.

‡ Professor of Medicine and Chief of Cardiology.

§ Professor and Chairman of Anesthesiology.

¶ Associate Professor of Pharmacology and Medicine, Division of Cardiology.

Received from the Departments of Anesthesiology, Pharmacology, and Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, and the Zablocki Veterans Administration Medical Center, Wood, Wisconsin. Accepted for publication March 6, 1989. Supported in part by USPHS Grant HL 36144, VA Medical Research Funds, and Cardiovascular Research Training Grant T32 HL 07546.

Address reprint requests to Dr. Warltier: Department of Pharmacology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, Wisconsin 53226.

of the Medical College of Wisconsin. Conditioned mongrel dogs of either sex, weighing 22–33 kg were anesthetized with sodium thiamylal (10 mg/kg, iv). After tracheal intubation, anesthesia was maintained with enflurane (2.0–2.5%) in 100% oxygen *via* a respirator (Monaghan 300 D/M). Ventilation was adjusted to maintain normal arterial blood gases. A positive end expiratory pressure of 5 cm of water was used to prevent atelectasis. A thoracotomy was performed in the left fifth intercostal space under sterile conditions. Heparin-filled catheters were inserted into the thoracic aorta and right atrial appendage for measurement of arterial pressure and drug administration, respectively. The heart was supported in a pericardial cradle. A precalibrated Doppler ultrasonic flow transducer (20 MHz) was placed on the proximal left anterior descending coronary artery for measurement of phasic and mean coronary blood flow velocity. Pairs of miniature ultrasonic segment length transducers (5 MHz) were implanted in a circumferential plane within the sub-endocardium (10–15 mm apart and 10 mm deep) in the region of the left ventricular free wall supplied by the left anterior descending artery for measurement of myocardial segment shortening. A miniature solid-state pressure gauge (P7 Konigsberg Instruments, Pasadena, CA) was implanted in the left ventricle through an incision in the apex. The rate of rise of left ventricular pressure (dp/dt_{50}) at 50 mmHg, an index of global left ventricular contractility, was obtained by electronic differentiation of the left ventricular pressure waveform. A catheter was positioned in the left atrial appendage. The left ventricular micromanometer was cross-calibrated *in vivo* against pressure measured *via* the arterial and left atrial fluid-filled catheters (Gould P50 pressure transducer, Oxnard, CA). All catheters and leads were secured, tunneled between the scapulae, and exteriorized *via* a small incision. The chest wall was closed in layers and pneumothorax evacuated by a chest tube.

After surgery, each dog was treated with chloramphenicol (1.5 g b.i.d., p.o.) and allowed to recover for a minimum of 7 days. During the postoperative period, the dogs were trained to stand quietly in a sling during monitoring of hemodynamics. Segment length and coronary blood flow velocity signals were driven and monitored *via* ultrasonic amplifiers (Hartley, Houston, TX). End systolic segment length (ESL) was determined at maximum negative left ventricular dp/dt , and end diastolic segment length (EDL) was determined at the onset of left ventricular isovolumetric contraction. The lengths were normalized according to the method of Theroux *et al.*¹² Percent segment shortening (%SS) was calculated by use of the equation: $\%SS = [(EDL - ESL) / EDL] \times 100$. Relative mean coronary vascular resistance was calculated as the quotient of mean aortic pressure (mmHg) and mean coronary blood flow velocity ($Hz \times 10^2$). All hemodynamic

data were recorded continuously on a Beckman polygraph (Sensormedics, Anaheim, CA) and digitized *via* a computer interfaced with an analog-to-digital converter.

EXPERIMENTAL PROTOCOL

Baseline recordings of hemodynamics were completed in the awake, unsedated dog. Hemodynamics were again recorded following ganglionic [hexamethonium (20 mg/kg, iv)], cholinergic [atropine methylnitrate (3 mg/kg, iv)], and beta adrenergic blockade [propranolol (2 mg/kg, iv)]. Systemic and coronary hemodynamic dose-response relationships were obtained to the α_1 adrenoceptor agonist, phenylephrine (0.3, 0.6, and 1.2 $\mu g/kg$, iv), or the α_2 adrenoceptor agonist, azepexole (5, 10, and 20 $\mu g/kg$, iv) in the conscious dogs. Adequacy of pharmacologic blockade of the autonomic nervous system was demonstrated by lack of reflex change in heart rate following abrupt increases in arterial pressure. Previous studies have demonstrated that the doses of hexamethonium, atropine methylnitrate, and propranolol are adequate to block hemodynamic responses to intravenous acetylcholine and isoproterenol.¹³ Hemodynamic responses were recorded at the time of peak effect of each agonist on systemic arterial pressure. Hemodynamics were allowed to return to baseline values before subsequent doses of agonists were given. Agonist doses were administered in a Latin square design. An ordered, numerical sequence of the various agonists and doses was utilized to avoid bias of any given specific drug sequence.

To determine the effects of halothane and isoflurane anesthesia on the pressor responses mediated by α_1 and α_2 adrenoceptor stimulation, each dog was anesthetized following characterization of dose-response relationships in the conscious state with concomitant ganglionic, cholinergic, and beta adrenergic blockade. Inhalation induction was accomplished with halothane or isoflurane in oxygen (30%) and nitrous oxide (70%) utilizing high flow rates. Following tracheal intubation, nitrous oxide was discontinued, positive pressure ventilation initiated, and anesthesia maintained with equihypotensive concentrations (approximately 2 MAC) of either halothane (1.7%) or isoflurane (2%) (corresponding to settings of a vaporizer previously calibrated with a mass spectrometer) in 100% oxygen (2 l/min) in separate groups. During each experiment, arterial blood samples were obtained at various intervals for measurement of blood gas tensions. Ventilation was adjusted to maintain arterial pH and pCO_2 within conscious levels. Hemodynamics were again recorded 1 h after anesthesia. The same doses of phenylephrine and azepexole as used in the conscious state were again administered in randomized fashion to the same dog and the hemodynamic responses recorded as above. Anesthesia was discontinued and emergence al-

TABLE 1. Summarized Hemodynamic Data Following Autonomic Nervous System Blockade and Halothane Anesthesia (Group 1)

	Control	ANS Blockade	Halothane
HR (bpm)	85 ± 6	118 ± 5*	100 ± 4*†
SBP (mmHg)	120 ± 6	92 ± 6*	86 ± 7*
DBP (mmHg)	84 ± 5	71 ± 6*	65 ± 7*
MBP (mmHg)	96 ± 5	78 ± 6*	72 ± 7*
LVSP (mmHg)	123 ± 5	95 ± 5*	90 ± 6*
LVEDP (mmHg)	8 ± 1	3 ± 1*	9 ± 2†
dP/dt ₅₀ (mmHg/s)	2087 ± 97	1625 ± 112*	1101 ± 100*†
MCBFV (Hz × 10 ²)	29 ± 5	26 ± 4	23 ± 3
MCVR (ru)	3.99 ± 0.68	3.48 ± 0.50	3.63 ± 0.58
SS (%)	19.2 ± 2.0	16.7 ± 2.5	14.0 ± 2.4*†

Values are mean ± SEM data (N = 10). HR = heart rate; LVSP and LVEDP = left ventricular systolic and end diastolic pressures; SBP, DBP, and MBP = systolic, diastolic, and mean blood pressures; MCBFV = mean coronary blood flow velocity; MCVR = mean coronary vascular resistance; SS = segment shortening.

* Significantly ($P < 0.05$) different from control.

† Significantly ($P < 0.05$) different from autonomic nervous system (ANS) blockade.

lowed to occur. Each dog was housed for at least 3 days prior to subsequent experimentation with the alternate volatile anesthetic. A total of 20 experiments in two separate groups (group 1: halothane [N = 10]; group 2: isoflurane [N = 10]) were completed using ten chronically instrumented dogs.

DRUGS

Fresh solutions of all drugs were prepared on the day of each experiment. Hexamethonium bromide, atropine methylnitrate, propranolol hydrochloride, azepexole hydrochloride (Boehringer Ingelheim, Ridgefield, CT), and phenylephrine hydrochloride were dissolved in 0.9% sodium chloride.

STATISTICAL ANALYSIS

Data are presented as mean ± SEM. Hemodynamic responses were compared to control by use of analysis of

TABLE 2. Summarized Hemodynamic Data Following Autonomic Nervous System Blockade and Isoflurane Anesthesia (Group 2)

	Control	ANS Blockade	Isoflurane
HR (bpm)	90 ± 8	118 ± 8*	103 ± 5*†
SBP (mmHg)	118 ± 5	90 ± 6*	80 ± 2*†
DBP (mmHg)	83 ± 4	67 ± 5*	55 ± 2*†
MBP (mmHg)	95 ± 4	75 ± 5*	63 ± 2*†
LVSP (mmHg)	120 ± 4	94 ± 6*	80 ± 2*†
LVEDP (mmHg)	7 ± 1	4 ± 1*	6 ± 1†
dP/dt ₅₀ (mmHg/s)	1953 ± 64	1654 ± 72*	1250 ± 99*†
MCBFV (Hz × 10 ²)	28 ± 3	28 ± 5	26 ± 4
MCVR (ru)	3.86 ± 0.55	3.38 ± 0.65	2.91 ± 0.42
SS (%)	19.9 ± 2.3	19.4 ± 1.7	15.4 ± 1.9*†

Values are mean ± SEM data (N = 10). See table 1 for abbreviations.

* Significantly ($P < 0.05$) different from control.

† Significantly ($P < 0.05$) different from autonomic nervous system (ANS) blockade.

variance with repeated measures followed by Dunnett's modification of the t test or Least Significant Difference (LSD) test. Changes between the conscious state, pharmacological blockade of the autonomic nervous system, and anesthesia, or following administration of α_1 and α_2 adrenoceptor agonists, were considered significant when the probability (P) value was less than 0.05.

Results

HEMODYNAMIC EFFECTS OF AUTONOMIC NERVOUS SYSTEM BLOCKADE

Hemodynamic alterations during autonomic nervous system blockade produced by administration of hexamethonium, atropine methylnitrate, and propranolol in groups 1 and 2 are shown in tables 1 and 2, respectively. Ganglionic, cholinergic, and beta adrenergic blockade produced significant ($P < 0.05$) reductions in left ventricular systolic and end diastolic pressures, mean arterial pressure, and left ventricular dP/dt₅₀ and increases in heart rate in both groups. Mean coronary blood flow velocity and coronary vascular resistance were unchanged.

HEMODYNAMIC EFFECTS OF VOLATILE ANESTHETICS

Hemodynamic effects of halothane anesthesia following autonomic nervous system blockade (group 1) are summarized in table 1. Halothane anesthesia produced a significant reduction in heart rate, left ventricular dP/dt₅₀, and %SS. Left ventricular systolic pressure and mean arterial pressure were only slightly reduced by halothane. In contrast, left ventricular end diastolic pressure was significantly increased. Mean coronary blood flow velocity and coronary vascular resistance were unchanged.

The hemodynamic changes during isoflurane anesthesia following autonomic nervous system blockade (group 2) are summarized in table 2. Similar to halothane, isoflurane produced reductions in heart rate, left ventricular dP/dt₅₀, %SS, and an increase in left ventricular end diastolic pressure. Mean coronary blood flow velocity and coronary vascular resistance were also unchanged following isoflurane. In contrast to halothane, isoflurane produced a significant decrease in both left ventricular systolic and arterial pressures. There was no significant difference in arterial pressure between the two groups after anesthesia.

ALPHA RECEPTOR STIMULATION IN CONSCIOUS DOGS

Summarized changes in systemic and coronary hemodynamics following intravenous bolus administration of phenylephrine (0.3, 0.6, and 1.2 $\mu\text{g}/\text{kg}$), and azepexole

TABLE 3. Changes in Systemic and Coronary Hemodynamics by Azepevole before and after Halothane Anesthesia

	Before Halothane Azepevole Dose (μg/kg)			After Halothane Azepevole Dose (μg/kg)		
	5	10	20	5	10	20
ΔHR (bpm)	-1 ± 1	-1 ± 1	-1 ± 1	1 ± 1	-1 ± 1	1 ± 1
ΔMBP (mmHg)	20 ± 2*	27 ± 1*	35 ± 3*	11 ± 1†*	17 ± 2†*	22 ± 2†*
ΔLVSP (mmHg)	17 ± 1*	24 ± 3*	29 ± 3*	9 ± 2†*	13 ± 2†*	17 ± 2†*
ΔLVEDP (mmHg)	2 ± 1	2 ± 1	3 ± 1	1 ± 1	2 ± 1	3 ± 1
ΔdP/dt ₅₀ (mmHg/s)	-56 ± 17	-80 ± 30*	-75 ± 15*	-33 ± 13	-19 ± 15	-35 ± 15
ΔMCFV (Hz × 10 ²)	1 ± 1	3 ± 1*	1 ± 2	1 ± 1	0 ± 1	0 ± 1
ΔMCVR (ru)	0.58 ± 0.09	0.77 ± 0.21*	1.39 ± 0.41*	0.60 ± 0.34*	0.95 ± 0.25*	1.21 ± 0.38*
ΔSS (%)	-0.2 ± 0.8	-2.5 ± 1*	-2.1 ± 1.4*	-0.2 ± 0.9	-1.8 ± 0.5	-1.7 ± 0.8

Values are mean ± SEM changes (Δ) from baseline (N = 10). See table 1 for abbreviations.

* Significantly (P < 0.05) different from baseline.

† Significantly (P < 0.05) different: Before vs. after halothane at comparable doses.

(5, 10, and 20 μg/kg) in ganglionic, cholinergic, and beta adrenergic blocked conscious dogs are shown in tables 3–6. Dose-related increases in arterial pressure were mediated by both alpha₁ and alpha₂ agonists. Systolic and diastolic aortic pressure and left ventricular systolic pressure were increased by all doses of both agonists. Left ventricular end diastolic pressure remained unchanged. Heart rate remained unchanged over the course of all experiments during abrupt pressor responses demonstrating continued and effective autonomic nervous system blockade. Both agonists caused an increase in coronary vascular resistance. There was a reduction in %SS concomitant with the abrupt increases in left ventricular afterload produced by both phenylephrine and azepevole.

in mean coronary blood flow velocity and vascular resistance produced by alpha₁ and alpha₂ agonists were unchanged by halothane.

Summarized systemic and coronary hemodynamic alterations produced by phenylephrine and azepevole before and after 1 h of isoflurane anesthesia (group 2) are shown in tables 5 and 6, respectively. Similar to halothane, isoflurane caused a significant attenuation of agonist-induced increases in systolic and diastolic arterial pressure (figs. 3 and 4). The responses of mean coronary blood flow velocity and vascular resistance were unchanged by isoflurane.

EFFECTS OF HALOTHANE AND ISOFLURANE ON ALPHA RECEPTOR MEDIATED RESPONSES

Systemic and coronary hemodynamic changes produced by phenylephrine and azepevole before and after 1 h of halothane anesthesia (group 1) are summarized in tables 3 and 4, respectively. Halothane attenuated the agonist-induced increases in systolic and diastolic arterial pressure (figs. 1 and 2) at each dose (P < 0.05). Changes

Discussion

Results of this investigation indicate that the alpha₁ agonist, phenylephrine, and the alpha₂ agonist, azepevole, produce qualitatively similar changes in the systemic and coronary hemodynamics measured. The results confirm the presence of two subpopulations of alpha adrenoceptors mediating pressor responses in the peripheral arterial bed of the dog. Both halothane and isoflurane nonselectively attenuated pressor responses to phenylephrine and azepevole in chronically instrumented dogs. Although both

TABLE 4. Changes in Systemic and Coronary Hemodynamics by Phenylephrine before and after Halothane Anesthesia

	Before Halothane Phenylephrine Dose (μg/kg)			After Halothane Phenylephrine Dose (μg/kg)		
	0.3	0.6	1.2	0.3	0.6	1.2
ΔHR (bpm)	-1 ± 1	1 ± 1	2 ± 1	-1 ± 1	0 ± 1	1 ± 1
ΔMBP (mmHg)	23 ± 2*	35 ± 3*	49 ± 5*	13 ± 1†*	20 ± 2†*	27 ± 2†*
ΔLVSP (mmHg)	21 ± 2*	29 ± 3*	42 ± 5*	11 ± 1†*	19 ± 2†*	27 ± 3†*
ΔLVEDP (mmHg)	3 ± 1	3 ± 1	6 ± 1	2 ± 1	5 ± 1	6 ± 1
ΔdP/dt ₅₀ (mmHg/s)	-23 ± 17	-21 ± 23	-63 ± 41*	-6 ± 14	-27 ± 27	-26 ± 27
ΔMCFV (Hz × 10 ²)	2 ± 1	3 ± 1	6 ± 3*	1 ± 1	1 ± 1	0 ± 1
ΔMCVR (ru)	0.66 ± .20*	1.09 ± .29*	1.26 ± 0.32*	0.41 ± 0.12	0.80 ± 0.20*	1.21 ± 0.23*
ΔSS (%)	-1.5 ± 0.9*	-2.6 ± 1.1*	-2.8 ± 1.3*	-1.2 ± 0.5*	-1.6 ± 0.7*	-2.3 ± 1.1*

Values are mean ± SEM changes (Δ) from baseline (N = 10). See table 1 for abbreviations.

* Significantly (P < 0.05) different from baseline.

† Significantly (P < 0.05) different: Before vs. after halothane at comparable doses.

TABLE 5. Changes in Systemic and Coronary Hemodynamics by Azepevole Following Autonomic Nervous System Blockade and Isoflurane Anesthesia

	Before Isoflurane Azepevole Dose (µg/kg)			After Isoflurane Azepevole Dose (µg/kg)		
	5	10	20	5	10	20
ΔHR (bpm)	1 ± 1	-1 ± 1	-1 ± 1	-1 ± 1	-2 ± 1	-1 ± 1
ΔMBP (mmHg)	24 ± 3*	26 ± 2*	37 ± 4*	15 ± 3†*	18† ± 1†*	27 ± 2†*
ΔLVSP (mmHg)	20 ± 3*	25 ± 2*	34 ± 5*	13 ± 3*	14 ± 2†*	21 ± 2†*
ΔLVEDP (mmHg)	2 ± 1	2 ± 1	3 ± 1	2 ± 1	2 ± 1	3 ± 1
ΔdP/dt ₅₀ (mmHg/s)	-33 ± 20	-59 ± 25*	-99 ± 20*	-51 ± 23	-31 ± 21	-55 ± 25
ΔMCBFV (Hz × 10 ²)	1.4 ± 0.6	2.8 ± 0.6	2.9 ± 1.1	1.9 ± 1.0	1.5 ± 0.8	1.1 ± 1.5
ΔMCVR (ru)	0.45 ± 0.23	0.53 ± 0.18*	0.91 ± 0.12*	0.36 ± 0.13	0.50 ± 0.11*	0.76 ± 0.11*
ΔSS (%)	-3.7 ± 2.9*	-3.4 ± 1.7*	-3.9 ± 0.9*	-1.6 ± 0.5	-2.9 ± 1.7*	-2.9 ± 1.3*

Values are mean ± SEM changes (Δ) from base line (N = 10). See table 1 for abbreviations.
* Significantly (P < 0.05) different from base line.

† Significantly (P < 0.05) different: Before vs. after isoflurane at comparable doses.

anesthetics decreased the pressor response to phenylephrine and azepevole in the peripheral vasculature, no significant changes were observed in the coronary circulation. Halothane and isoflurane, as well as autonomic nervous system blockade, had minimal effects on coronary hemodynamics in the present study. The lack of effect of autonomic blockade may be explained in that metabolic autoregulation and alpha-adrenergic constrictor tone remained intact.¹⁴ Reasons for the lack of action of halothane and isoflurane are unknown and surprising in that coronary blood flow autoregulation has been described to be mildly disrupted by these agents in chronically instrumented dogs.¹⁵

Chronically instrumented dogs were used in this study to eliminate the influence of surgical trauma and basal anesthesia on pharmacologically mediated pressor responses. Autonomic nervous system blockade was produced by administration of hexamethonium, atropine methylnitrate, and propranolol to eliminate reflex changes mediated by cholinergic or beta-adrenergic nervous system stimulation. In addition, the effects of the volatile anesthetics on the beta adrenergic or parasympathatic

nervous system were eliminated. Anesthetic concentrations were not measured in gas or blood phases, and this represents a possible limitation of the study, although the anesthetics were delivered from a vaporizer calibrated with a mass spectrometer, and the animals were allowed to stabilize for 1 h. Blockade of resting ganglionic, beta adrenergic, and parasympathetic tone resulted in a significant increase in heart rate and decrease in aortic blood pressure and dP/dt₅₀ without change in coronary hemodynamics.

Halothane and isoflurane produce vasodilation by direct relaxation of vascular smooth muscle *in vitro*.¹⁶ Whether a portion of this response is mediated *in vivo* through inhibition of sympathetic vasoconstriction at the level of the postjunctional alpha receptor or by mechanisms involved in alpha-adrenergic vasoconstriction which lie distal to the receptor is unknown. In this investigation, halothane and isoflurane reduced the pressor response to selective alpha₁ and alpha₂ agonists. The selectivity of phenylephrine and azepevole for alpha₁ and alpha₂ vascular receptors, respectively, has been well established.⁹ Wynsen *et al.*³ have shown that in conscious dogs, a re-

TABLE 6. Changes in Systemic and Coronary Hemodynamics by Phenylephrine before and after and Isoflurane Anesthesia

	Before Isoflurane Phenylephrine Dose (µg/kg)			After Isoflurane Phenylephrine Dose (µg/kg)		
	0.3	0.6	1.2	0.3	0.6	1.2
ΔHR (bpm)	-1 ± 1	1 ± 1	2 ± 1	-1 ± 1	-1 ± 1	1 ± 1
ΔMBP (mmHg)	24 ± 5*	40 ± 4*	55 ± 6	16 ± 2†*	27 ± 3†*	38 ± 3†*
ΔLVSP (mmHg)	20 ± 4*	36 ± 3*	48 ± 8*	14 ± 2†*	23 ± 2†*	35 ± 4†*
ΔLVEDP (mmHg)	4 ± 2	5 ± 2	7 ± 2*	2 ± 1	3 ± 1	5 ± 1
ΔdP/dt ₅₀ (mmHg/s)	-35 ± 45	-61 ± 33	-17 ± 67*	-21 ± 25	-33 ± 29	-8 ± 39
ΔMCBFV (Hz × 10 ²)	3.7 ± 1.8	3.4 ± 1	3.9 ± 1.4	1.4 ± 0.8	3.4 ± 1.5	2.2 ± 1.7
ΔMCVR (ru)	0.13 ± 0.28	0.94 ± 0.13*	1.19 ± 0.20*	0.39 ± 0.09	0.53 ± 0.13	1.19 ± 0.25*
ΔSS (%)	-3.5 ± 1.3*	-3.9 ± 1.0*	-5.3 ± 1.0*	-3.1 ± 0.7*	-3.5 ± 1.5*	-3.2 ± 1.3*

Values are mean ± SEM changes (Δ) from baseline (N = 10). See table 1 for abbreviations.
* Significantly (P < 0.05) different from baseline.

† Significantly (P < 0.05) different: Before vs. after isoflurane at comparable doses.




FIG. 1. Changes in systolic and diastolic blood pressure (SBP and DBP, respectively) produced by azepevole (5, 10, and 20 µg/kg) (mean ± SEM; N = 10) before (open squares) and after (closed squares) 1 h of halothane anesthesia. *Significantly ($P < 0.05$) different: before vs. after halothane.

duction of arterial pressure does not cause a preferential attenuation of the α_2 pressor responses.³ Vasodilator agents with different mechanisms of action may differentially alter the pressor response to α_1 and α_2 agonists.

The mechanism by which halothane and isoflurane reduced the pressor response mediated by alpha adrenergic receptors is unclear. Larach *et al.*⁶ recently demonstrated that halothane selectively attenuated α_2 adrenoceptor-mediated vasoconstriction in pithed rats and in canine saphenous vein rings. However, other work *in vitro* utilizing isolated vascular strips has suggested that both halothane and isoflurane may also interfere with α_1 -mediated vasoconstriction.¹⁶

Larach *et al.*⁶ and others¹⁷ have suggested that α_1 -mediated vasoconstriction (*e.g.*, phenylephrine-induced)

results from the entry of extracellular calcium and/or the release of stored intracellular calcium. In contrast, α_2 -mediated vasoconstriction, *e.g.*, by the selective agonist, azepevole has been shown to be primarily dependent on an influx of extracellular calcium¹⁸ and is sensitive to calcium-entry blockade with calcium antagonists.¹⁹ Larach *et al.*⁶ have suggested that halothane may interfere with α_2 excitation-contraction coupling by limiting the influx of extracellular calcium *via* calcium channels in vascular smooth muscle cells. Such an action may explain the results obtained in the canine saphenous vein preparation and in the pithed rat model.⁶ The observation of Larach *et al.*⁶ that halothane did not antagonize α_1 constriction of the canine saphenous vein *in vitro* may also be partially explained by the presence of a large α_1 adrenoceptor reserve. Receptor reserve may conceal an un-




FIG. 2. Changes in systolic and diastolic blood pressure (SBP and DBP, respectively) produced by phenylephrine (0.3, 0.6, and 1.2 $\mu\text{g}/\text{kg}$) (mean \pm SEM; N = 10) before (open squares) and after (closed squares) 1 h of halothane anesthesia. *Significantly ($P < 0.05$) different: before vs. after halothane.

derlying antagonism to α_1 adrenoceptor-mediated responses in canine saphenous vein²⁰ and in pithed rats.²¹ Similarly, Lew and Angus²² have shown that hypotension induced by hemorrhage, nitroprusside, or nifedipine preferentially inhibited the pressor effect of a selective α_2 agonist in the pithed rat. Recent evidence has also suggested that the relative susceptibility of α_2 mediated vasoconstriction to calcium antagonists may simply be due to a reserve population of α_1 adrenoceptors.²³ Spare α_1 receptors may also serve to conceal an underlying functional antagonism to calcium entry blockade. Thus, the selective inhibition of α_2 -mediated vasoconstriction may not be due to interference with the calcium excitation-contraction coupling mechanism, but instead to a large α_1 adrenoceptor reserve.

Not all experimental evidence has supported the hy-

pothesis of a receptor reserve^{24,25} to account for the inhibition of α_1 receptor-induced vasoconstriction by calcium antagonists. It has been suggested that α_1 -adrenoceptor agonists can be subdivided into those eliciting calcium entry dependent and independent vasoconstriction *in vivo*, and that this would explain the variable susceptibility of α_1 -adrenoceptor-mediated pressor responses to inhibition calcium channel blocking agents.²⁶ In the conscious dog, the postsynaptic vascular α_1 and α_2 receptor pressor response is associated with an influx of extracellular calcium.²⁷ While α_1 - and α_2 -mediated pressor responses are highly susceptible to calcium entry blockade in both anesthetized²⁸ and conscious dogs,⁸ and humans,²⁹ these studies are in sharp contrast to other investigations in pithed rats, cats, and rabbits.³⁰ Thus, it is possible that these results are species dependent, and




FIG. 3. Changes in systolic and diastolic blood pressure (SBP and DBP, respectively) produced by azepexole (5, 10, and 20 µg/kg) (mean ± SEM; N = 10) before (open squares) and after (closed squares) 1 h of isoflurane anesthesia. *Significantly ($P < 0.05$) different: before *vs.* after isoflurane.

results obtained in the conscious dog may be closer to the human than in the pithed rat.

In the present investigation, the dose response curves for phenylephrine and azepexole were shifted to the right by both halothane and isoflurane. Such a shift is consistent with the anesthetics acting as functional antagonists to phenylephrine and azepexole. These results are similar to those obtained by Woodman *et al.*⁸ and Wynsen *et al.*³ which demonstrated that nifedipine attenuated the pressor responses to both α_1 and α_2 adrenoceptor agonists in the conscious dog without selectivity for either receptor subtype. Although halothane and isoflurane have important effects on calcium metabolism in cardiac muscle,³¹ and have a direct relaxing action on vascular smooth muscle,¹⁶ the volatile anesthetics probably do not act as classic calcium channel-blocking agents.³² While the

mechanism of calcium utilization in vasoconstriction induced by alpha adrenergic activation is unresolved,¹⁷ it is possible that halothane and isoflurane interfere with changes in calcium in vascular smooth muscle following alpha adrenoceptor stimulation, but further experiments are required to determine the precise mechanisms involved.

Although this study has demonstrated that α_1 and α_2 pressor responses are attenuated by halothane and isoflurane in the chronically instrumented dog, it is unclear if this inhibitory action is confined to the alpha receptor or represents a nonspecific action of these anesthetics. Halothane has been shown to inhibit norepinephrine release from sympathetic nerve endings³³ and to reduce the oxidative deamination of norepinephrine in canine saphenous vein.³⁴ This would not explain the pres-




FIG. 4. Changes in systolic and diastolic blood pressure (SBP and DBP, respectively) produced by phenylephrine (3, 6, and 1.2 $\mu\text{g}/\text{kg}$) (mean \pm SEM; N = 10) before (open squares) and after (closed squares) 1 h of isoflurane anesthesia. *Significantly ($P < 0.05$) different: before vs. after isoflurane.

ent results since phenylephrine and azepexol \acute{e} are specific agonists which act directly on the alpha adrenergic receptor. Blaise *et al.*³⁵ have previously demonstrated that isoflurane attenuated vasoconstriction induced by serotonin, phenylephrine, and prostaglandin F 2α in isolated canine arteries. These investigators reported that the only direct effect of isoflurane on vascular smooth muscle was a moderate alpha adrenergic inhibitory action since isoflurane depressed contractions evoked by phenylephrine in rings of coronary arteries devoid of endothelium. Furthermore, it was also demonstrated³⁵ that isoflurane had no effect on the tension generated by isolated coronary arteries contracted with potassium. This may suggest that the effect of isoflurane on alpha $_1$ and alpha $_2$ pressor re-

sponses in the present investigation is specific. Muldoon *et al.*³⁶ have shown that contractions induced by norepinephrine in canine carotid and rabbit aortic arch preparations were significantly diminished by halothane, although halothane did cause an increase in the tension induced by norepinephrine in isolated canine femoral arteries. Vatner and Smith³⁷ also observed variable responses of halothane in different vascular beds in chronically instrumented dogs. Regional variation³⁸ in alpha adrenergic receptor subtype in the dog may explain such results. In general, the present study demonstrates that alpha $_1$ and alpha $_2$ pressor responses are attenuated by halothane and isoflurane in the chronically instrumented dog.

Thus, the mechanism of inhibition of α_1 and α_2 adrenoceptors by halothane and isoflurane remains unclear; however, the present investigation demonstrates that both volatile anesthetics interfere with the vasoconstriction produced by α_1 and α_2 adrenoceptor stimulation in a nonselective manner in the canine model.

The authors wish to thank Carol Knapp and Tammi Steward for the preparation of the manuscript, and John Tessmer, Anna Husa, and David Schwabe for excellent technical assistance.

References

1. Langer SZ, Duval N, Massingham R: Pharmacologic and therapeutic significance of alpha-adrenoceptor subtypes. *J Cardiovasc Pharmacol* 7 [Suppl 8]:S1-S8, 1985
2. Jie K, Van Brummelen P, Vermey P, Timmermans PB, Van Zwieten PA: Identification of vascular postsynaptic α_1 - and α_2 -adrenoceptors in man. *Circ Res* 54:447-452, 1984
3. Wynsen JC, Gross GJ, Brooks HL, Warltier DC: Differential effects of nifedipine, nicorandil and nitroglycerin on the pressor response elicited by selective alpha-1 and alpha-2 adrenoceptor agonists in conscious dogs. *J Pharmacol Exp Ther* 241:846-854, 1987
4. Merin RG, Kumazawa T, Luka NL: Myocardial function and metabolism in the conscious dog and during halothane anesthesia. *ANESTHESIOLOGY* 44:402-415, 1976
5. Eger EI: Isoflurane. A Review. *ANESTHESIOLOGY* 55:559-576, 1981
6. Larach DR, Schuler HG, Derr JA, Larach MG, Hensley FA Jr, Zelis R: Halothane selectively attenuates alpha-2 adrenoceptor mediated vasoconstriction, *in vivo* and *in vitro*. *ANESTHESIOLOGY* 66:781-791, 1987
7. Cavero I, Shepperson N, Lefevre-Borg F, Langer SZ: Differential inhibition of vascular smooth muscle responses to α_1 and α_2 -adrenoceptor agonists by diltiazem and verapamil. *Circ Res* 52 [Suppl 1]:I69-I76, 1983
8. Woodman OL, Constantine JW, Vatner SF: Nifedipine attenuates both alpha-1 and alpha-2 adrenoceptor mediated pressor and vasoconstrictor responses in conscious dogs and primates. *J Pharmacol Exp Ther* 239:648-653, 1986
9. Van Meel JCA, De Jonge A, Timmermans PBM, Van Zwieten PA: Selectivity of some alpha adrenoceptor agonists for peripheral alpha-1 and alpha-2 adrenoceptors in the normotensive rat. *J Pharmacol Exp Ther* 219:760-767, 1981
10. Vatner SF, Braunwald E: Cardiovascular control mechanisms in the conscious state. *N Engl J Med* 293:970-976, 1975
11. Fujii AM, Vatner SF: Baroreflex mechanisms buffering α -adrenergic agonists in conscious dogs. *Am J Physiol* 253:H728-H736, 1987
12. Theroux P, Franklin D, Ross J Jr, Kemper WS: Regional myocardial function during acute coronary artery occlusion and its modifications by pharmacological agents in the dog. *Circ Res* 35:896-908, 1974
13. Riley DC, Schmeling WT, Al-Wathiqui MH, Kampine JP, Warltier DC: Prolongation of the QT interval by volatile anesthetics in chronically instrumented dogs. *Anesth Analg* 67:741-749, 1988
14. Vatner SF: Alpha-adrenergic regulation of the coronary circulation in the conscious dog. *Am J Cardiol* 52:15A-21A, 1983
15. Hickey RF, Sybert PE, Verrier ED, Cason BA: Effects of halothane, enflurane and isoflurane on coronary blood flow autoregulation and coronary vascular reserve in the canine heart. *ANESTHESIOLOGY* 68:21-30, 1988
16. Sprague DH, Yang JC, Ngai SH: Effects of isoflurane and halothane on contractility and the cyclic 3',5'-adenosine monophosphate system in the rat aorta. *ANESTHESIOLOGY* 40:2, 162-167, 1974
17. Timmermans PBMWM, Chiu AT, Thoolen MJMC: Calcium handling in vasoconstriction to stimulation of α_1 - and α_2 -adrenoceptors. *Can J Physiol Pharmacol* 65:1649-1657, 1987
18. Van Meel JCA, de Jonge A, Kalkman HO, Wilffert B, Timmermans PB, van Zwieten PA: Vascular smooth muscle contraction initiated by post synaptic α_2 -adrenoceptor activation is induced by an influx of extracellular calcium. *Eur J Pharmacol* 69:205-208, 1981
19. Van Zwieten PA, Timmermans PBMWM, Thoolen MJMC, Wilffert B, de Jong A: Calcium dependency of vasoconstriction mediated by α_1 - and α_2 -adrenoceptors. *J Cardiovasc Pharmacol* 7 [Suppl 6]:S113-S120, 1985
20. Eskinder H, Gross GJ: Differential inhibition of alpha-1 vs. alpha-2 adrenoceptor-mediated responses in canine saphenous vein by nitroglycerin. *J Pharmacol Exp Ther* 238:515-521, 1986
21. Ruffolo RR Jr, Morgan EL, Messick K: Possible relationship between receptor reserve and the differential antagonism of alpha-1 and alpha-2 adrenoceptor-mediated pressor responses by calcium channel antagonists in the pithed rat. *J Pharmacol Exp Ther* 230:587-594, 1984
22. Lew MJ, Angus JA: α_1 and α_2 -adrenoceptor-mediated pressor responses: Are they differentiated by calcium antagonists or by functional antagonism? *J Cardiovasc Pharmacol* 7:401-408, 1985
23. Bogнар IT, Enero MA: Influence of a receptor reserve on the inhibition by calcium channel blockers on alpha adrenoceptor-mediated responses in rat isolated vascular tissues. *J Pharmacol Exp Ther* 245:673-681, 1988
24. Timmermans PBMWM, Thoolen MJMC: Equal potency of nifedipine to inhibit α_1 -(dobutamine and BDF 6143) and α_2 -adrenoceptor (B-HT 920) induced pressor responses in pithed rats; lack of effect of phenoxybenzamine. *Eur J Pharmacol* 140:133-142, 1987
25. Timmermans PBMWM, Thoolen MJMC, Mathy MJ, Wilffert B, de Jonge A, van Zwieten PA: Effects of the irreversible α -adrenoceptor antagonists phenoxybenzamine and benextramine on the effectiveness of nifedipine in inhibiting α_1 - and α_2 -adrenoceptor mediated vasoconstriction in pithed rats. *Naunyn Schmiedeberg Arch Pharmacol* 329:404-413, 1985
26. Wilffert B, van Heiningen PNM, Mathy MJ, Batink HD, de Jonge A, Thoolen MJMC, Timmermans PBMWM, van Zwieten PA: Lack of relationship between intrinsic activity and susceptibility of pressor responses to blockade by nifedipine among the α_2 -adrenoceptor agonists B-HT 920 and B-HT 958. *Naunyn Schmiedeberg Arch Pharmacol* 327:90-92, 1984
27. Wynsen JC, Gross GJ, Brooks HL, Warltier DC: Changes in adrenergic pressor responses by calcium channel modulation in conscious dogs. *Am J Physiol* 253:H531-H539, 1987
28. Morita T, Maniwa T, Satoh K, Taira N: Undifferentiated effects of calcium antagonists on pressor responses to selective alpha-1 and alpha-2 adrenoceptor agonists in anesthetized, spinal dogs. *J Pharmacol Exp Ther* 234:728-734, 1985
29. Reid JL, Pasanisi F, Meredith PA, Elliott HL: Clinical pharmacological studies on the interaction between α -adrenoceptors and calcium antagonists. *J Cardiovasc Pharmacol* 7 [Suppl 6]: S206-S209, 1985
30. Van Zwieten PA, Van Meel JCA, Timmermans PB: Functional

- interaction between calcium antagonists and the vasoconstriction induced by the stimulation of postsynaptic α_2 adrenoceptors. *Circ Res* 52 [Suppl 1]:77-80, 1983
31. Lynch C: Effects of halothane and isoflurane on isolated human ventricular myocardium. *ANESTHESIOLOGY* 68:429-432, 1988
 32. Lynch C: Are volatile anesthetics really calcium entry blockers? *ANESTHESIOLOGY* 61:644-646, 1984
 33. Rorie DK, Tyce GM, Mackenzie RA: Evidence that halothane inhibits norepinephrine release from sympathetic nerve endings in dog saphenous vein by stimulation of presynaptic inhibitory muscarinic receptors. *Anesth Analg* 63:1059-1064, 1984
 34. Lunn JJ, Rorie DK: Halothane-induced changes in the release and disposition of norepinephrine at adrenergic nerve endings in dog saphenous vein. *ANESTHESIOLOGY* 61:377-384, 1984
 35. Blaise G, Sill JC, Nugent M, Van Dyke RA, Vanhoutte PM: Isoflurane causes endothelium-dependent inhibition of contractile responses of canine coronary arteries. *ANESTHESIOLOGY* 67: 513-517, 1987
 36. Muldoon SM, Hart JL, Bowen KA, Freas W: Attenuation of endothelium-mediated vasodilation by halothane. *ANESTHESIOLOGY* 68:31-37, 1988
 37. Vatner SF, Smith NT: Effects of halothane on left ventricular function and distribution of regional blood flow in dogs and primates. *Circ Res* 34:155-167, 1974
 38. Horn PT, Kohli JD, Listinsky JJ, Goldberg LI: Regional variation in the alpha-adrenergic receptors in the canine resistance vessels. *Naunyn Schmiedeberg Arch Pharmacol* 318:166-172, 1982